Olmesartan Medoxomil in Atherosclerosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00185185|
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : December 14, 2007
|Condition or disease||Intervention/treatment||Phase|
|Essential Hypertension Atherosclerotic Cardiovascular Disease||Drug: Olmesartan medoxomil Drug: Atenolol Drug: Hydrochlorothiazide Drug: olmesartan medoxomil Drug: atenolol||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||165 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)|
|Study Start Date :||November 2001|
|Actual Study Completion Date :||February 2006|
Drug: Olmesartan medoxomil
Drug: olmesartan medoxomil
Active Comparator: 2
- Change of intima media thickness of the common carotid artery on the leading side of the neck.
- -Change in plaque volume in the common carotid artery or the carotid bulb.
- -Change of intima media thickness of the common carotid artery.
- -Changes of diastolic and systolic blood pressure.
- -Safety and tolerability
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00185185
|Principal Investigator:||Prof. Klaus O Stumpe, MD||Medizinische Poliklinik der Friedrich-Wilhelms-Universitat, Bonn, Germany|